The findings have important clinical implications by highlighting Gal-9 as a promising therapeutic target for A-T Syndrome and ATM-deficient tumors and revealing combining ATM inhibition with anti-Gal-9 therapy as a novel strategy for cancer treatment. Here, LGALS9 is linked to cancer.